Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 18/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20185038 | 1.00 | KDM4E (0.46) | KDM4EHSD17B10IRAK4TNKSIRAK1 | |
| SCHEMBL20185045 | 1.00 | KDM4E (0.46) | KDM4EHSD17B10IRAK4TNKSIRAK1 | |
| SCHEMBL20185046 | 1.00 | KDM4E (0.46) | KDM4EHSD17B10IRAK4TNKSIRAK1 | |
| SCHEMBL18208327 | 1.00 | KDM4E (0.46) | KDM4EHSD17B10IRAK4TNKSIRAK1 | |
| SCHEMBL18208323 | 1.00 | KDM4E (0.46) | KDM4EHSD17B10IRAK4TNKSIRAK1 | |
| SCHEMBL20118186 | 0.86 | KDM4E (0.46) | KDM4EHSD17B10IRAK4TNKS | |
| SCHEMBL18208502 | 0.85 | IRAK4 (0.49) | KDM4EHSD17B10IRAK4TNKSIRAK1 | |
| SCHEMBL18209065 | 0.85 | IRAK4 (0.49) | KDM4EHSD17B10IRAK4TNKSIRAK1 | |
| SCHEMBL18208548 | 0.85 | IRAK4 (0.49) | KDM4EHSD17B10IRAK4TNKSIRAK1 | |
| SCHEMBL18208197 | 0.84 | IRAK4 (0.48) | KDM4EHSD17B10IRAK4IRAK1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
| WO-2016177658-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | C1R, C9, C1S | KDM4E 2120/4885HSD17B10 1415/4885IRAK4 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.